spacer
home > ict > winter 2021 > forecasting for success
PUBLICATIONS
International Clinical Trials

Forecasting for Success


In recent years, the pharmaceutical industry has seen tremendous changes in the way it is expected to deliver new drugs to market – being under increasing pressure to shorten drug development timelines, make significant cost savings, and drive technological advances forward, at the same time. Clinical trial forecasting is a crucial component to this success and is essential for minimising trial waste and unnecessary costs.

Accurate forecasting also ensures that required materials are available to dispense to patients, and reduces the risk of patient enrolment restrictions. Continued maintenance of the forecast throughout a study’s lifecycle will help avoid a stockout situation and keep waste to a minimum. Recruitment freezes and missed doses could potentially delay bringing drugs to market, while excessive waste can prove costly.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sarah Jane Hayward is a Senior Clinical Supply Manager at PCI Clinical Trial Services and part of the International Supply Readiness and Management Team (SMART) An experienced global project manager, Sarah has over 15 years’ experience working for pharma companies and CROs, specialising in the production and global supply of clinical trial materials.

Slava Shulov is a Senior Clinical Supply Manager at PCI Clinical Trial Services and part of the International Supply Readiness and Management Team (SMART). Slava is an experienced global project manager in the fields of global clinical operations, manufacturing, and supply chain. Slava has extensive experience in global supply chain project management, knowledge of ICH/GCP, and monitoring the conduct of clinical trials. Slava holds a degree in Life Science from the Technion – Israel Institute of Technology.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Invests More than €130 Million to Strengthen Manufacturing Capabilities in Molsheim, France

Merck, a leading science and technology company, strengthens its manufacturing capabilities for single-use assemblies, a key technology for the production of Covid-19 vaccines and other lifesaving therapies, by investing more than € 130 million in Molsheim, France. The investment is the largest ever in the 50-year history of the site and will create more than 800 jobs by the end of 2028.
More info >>

White Papers

Using Device Strategy to Drive R&D Productivity

Phillips-Medisize


More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement